1. INTRODUCTION
===============

Anemia is a common finding in cancer patients and can be a result of treatment or of underlying disease [@b1-co15_s1p010]. A large-scale audit of blood transfusions in 2719 cancer patients showed that 38% had a hemoglobin level below 11.0 g/dL during chemotherapy and that 33% of the patients required at least one blood transfusion.[@b2-co15_s1p010].

Recombinant human erythropoietin was first used clinically in renal dialysis patients in the 1980s, at which time it was shown to correct anemia in end-stage renal disease[@b3-co15_s1p010]. Those findings led to a recognition that anemia in patients with malignancy might also be able to be reversed, leading to an improvement in hemoglobin level, rate of transfusion, and quality of life ([qol]{.smallcaps}).

The first randomized trial in cancer patients demonstrated that recombinant human erythropoietin is effective for treating anemia in cancer patients on chemotherapy[@b4-co15_s1p010]. Three large, open, nonrandomized trials confirmed that finding and, more importantly, established that the highest incremental improvement in [qol]{.smallcaps} was achieved at an optimum hemoglobin level of 12 g/dL [@b5-co15_s1p010]--[@b7-co15_s1p010]. That level of 12 g/dL is now considered the accepted level by various guidelines committees, including those of the American Society of Hematology [@b8-co15_s1p010], the American Society of Clinical Oncology [@b9-co15_s1p010], and the National Comprehensive Cancer Network [@b10-co15_s1p010]. (The 12 g/dL level will be important to remember in the exploration of publications reporting negative safety and survival in the remainder of the present article.)

After the open-label studies, a randomized placebo-controlled study by Littlewood *et al.* [@b11-co15_s1p010] confirmed the relationship between anemia, fatigue, and [qol]{.smallcaps}. A retrospective review in that trial suggested a survival advantage in patients treated with epoetin alfa. That finding led to prospective trials that attempted to validate the better-survival hypothesis. To strengthen the argument, higher-than-normal hemoglobin levels were defined for achievement. As well, to broaden the indications for use, trials were conducted in patients not on active chemotherapy treatment. Neither of those strategies worked, and confusion regarding the safety of this class of drugs instead resulted. To complicate the data even more, the media have been emphasizing the profit margins of the pharmaceutical companies managing the drugs.

The aim of the present article is to critically review the benefits and risks associated with the use of erythropoiesis-stimulating agents ([esa]{.smallcaps}s) as supportive care in cancer patients. Demonstrated benefits of [esa]{.smallcaps}s include lower rates of transfusion and improved [qol]{.smallcaps}, including reduced fatigue and better cognition. Demonstrated risks of [esa]{.smallcaps}s include risk of thromboembolic disease, negative impact on survival, and risk of tumour proliferation.

2. BENEFITS
===========

2.1 Lower Rates of Transfusion
------------------------------

Two [esa]{.smallcaps}s, epoetin alfa (Eprex: Janssen--Ortho, Toronto, ON) and darbepoetin alfa (Aranesp: Amgen, Thousand Oaks, CA, U.S.A.) are approved in Canada. The basis for this approval by the Health Protection Branch of Health Canada and the U.S. Food and Drug Administration ([fda]{.smallcaps}) was a proven reduction (as compared with placebo) in the proportion of patients transfused during chemotherapy.

Six randomized placebo-controlled double-blind clinical trials using epoetin alfa were pooled [@b12-co15_s1p010]. Anemic cancer patients (*n* = 131) who were to receive at least 12 weeks of concurrent chemotherapy were randomized (1:1) to receive epoetin alfa 150 U/kg or placebo subcutaneously three times weekly for 12 weeks. Half of the patients received cisplatin-containing chemotherapy regimens. Efficacy results showed a reduction in transfusions by approximately 50% during the second and third months of chemotherapy in the patients treated with epoetin alfa. [Table I](#tI-co15_s1p010){ref-type="table"} summarizes the results.

Approval of darbepoetin alfa for the treatment of anemia in cancer patients on chemotherapy was also based on a proven reduction in transfusions. A phase III double-blind placebo-controlled randomized (1:1) study of darbepoetin alfa was preformed in anemic patients with untreated non-small-cell or small-cell lung cancer who were to receive at least 12 weeks of platinum-containing chemotherapy [@b13-co15_s1p010]. A total of 314 patients were randomized to darbepoetin alfa 2.25 μg/kg or placebo subcutaneously weekly. Patients were stratified by tumour type. As in the epoetin alfa trial, efficacy results for treatment with darbepoetin alfa showed an approximately 50% reduction in transfusions, a result that was significant from week 5 through the end of treatment. [Table II](#tII-co15_s1p010){ref-type="table"} summarizes the results.

The risks of blood transfusion must be understood. The most common serious risk of red cell transfusion is transfusion-related acute lung injury. The risk of this complication is estimated to be 1 in 432 whole-blood units to 1 in 557,000 red-blood-cell units [@b14-co15_s1p010]. The risk of infection with human blood products changes with time and has improved since the late 1990s because of the application of careful screening techniques for antibodies against [hiv]{.smallcaps}, hepatitis [b]{.smallcaps} and [c]{.smallcaps}, and West Nile virus. In 1991, the risk of [hiv]{.smallcaps} was 1 in 493,000; in 2003, it was estimated at less than 1 in 1,000,000 [@b15-co15_s1p010]. But it is the unknown bacterium or virus that cannot be uncovered through testing. For that reason, the Kreever Commission recommended that "the operator of the blood supply system promote appropriate use of, and alternatives to, blood components and blood products. Blood components and blood products will never be without risk. The best way to reduce that risk is to reduce their use" [@b16-co15_s1p010]. For liability reasons, hospital authorities ask doctors and their patients to sign consent forms acknowledging that the patient understands the risk of such procedures. It would be short-sighted and naïve to believe that another infectious agent will never be seen in human blood products.

In summary, [esa]{.smallcaps}s are efficacious in reducing the need for blood transfusions in cancer patients on chemotherapy. Across several studies, approximately 50% of patients on chemotherapy without [esa]{.smallcaps}s required transfusions, as compared with 20% of patients receiving [esa]{.smallcaps}s while on chemotherapy. Blood transfusions have a fairly high-safety profile, but the risk of infectious components continues to be a concern. The risk is always evolving as new infectious agents are found within human donor products. The risk of blood transfusions must constantly be weighed against their benefit.

2.2 Improvement in QOL
----------------------

Other than minimizing the need for blood transfusions, one of the main reasons that physicians order [esa]{.smallcaps}s for their patients on chemotherapy is to achieve an improvement in [qol]{.smallcaps}. As duration of survival increases, [qol]{.smallcaps} is increasingly being perceived as an important goal in the management of cancer. Symptoms of anemia include dyspnea, weakness, tachycardia, impaired cognition, depression, and fatigue. It is understandable how all of those symptoms may lead to diminished [qol]{.smallcaps} and how avoidance of anemia and subsequent symptoms may lead to improved [qol]{.smallcaps}.

When epoetin alfa and darbepoetin alfa were approved in Canada and the United States, they were approved for their statistically significant reduction in the requirement for transfusions. They did not meet criteria set out by the U.S. [fda]{.smallcaps} for approval for the indication of [qol]{.smallcaps} improvement. Those [fda]{.smallcaps} criteria are extensive, and they include [@b17-co15_s1p010]

-   use of validated instruments;

-   double-blinding of personnel administering the [qol]{.smallcaps} questionnaires;

-   prospective identification of key outcomes, critical time points, and minimum differences in scores to be considered clinically significant; and

-   a detailed plan for preventing missing data, investigating the pattern of missing data, and addressing missing data in the analysis.

Although not meeting the foregoing criteria, multiple trials have reported a positive correlation between [esa]{.smallcaps} use and improvement in [qol]{.smallcaps}. The strongest evidence comes from a randomized controlled trial by Littlewood *et al.* [@b11-co15_s1p010]. That trial enrolled 375 patients with a mean baseline hemoglobin of 10 g/dL. Of the 375 patients, 335 were evaluable for [qol]{.smallcaps} outcomes, which were evaluated using the Functional Assessment of Cancer Therapy--Anemia ([fact]{.smallcaps}-[an]{.smallcaps}) instrument and the Linear Analogue Self-Assessment ([lasa]{.smallcaps}) scales. Positive, statistically significant differences between the [esa]{.smallcaps}-treated and untreated groups were found. Results from the Medical Outcomes Study Short Form--36 ([sf]{.smallcaps}--36) showed a trend in the same direction, but did not reach significance ([Table III](#tIII-co15_s1p010){ref-type="table"}). Criticism of the trial focused on missing descriptions of the key methodologic features for administering the [qol]{.smallcaps} instruments. As well, the study did not prospectively define the minimum changes in [qol]{.smallcaps} score that would be considered clinically significant.

Although not meeting [fda]{.smallcaps} requirements, three large community-based nonrandomized open-label studies performed with epoetin alfa can still provide insights. Those studies enrolled a total of 7724 patients, of whom 7283 were assessable. Epoetin alfa was administered to anemic patients with non-myeloid malignancies undergoing standard chemotherapy. Glaspy *et al.* [@b5-co15_s1p010] and Demetri *et al.* [@b6-co15_s1p010] used 3-times-weekly dosing, and the third study by Gabrilove *et al.* [@b7-co15_s1p010] used once-weekly dosing. Measures of [qol]{.smallcaps} included the [fact]{.smallcaps}-General, the [fact]{.smallcaps}-[an]{.smallcaps} subscale, and the [lasa]{.smallcaps}. The validated cancer-specific [lasa]{.smallcaps} instrument, which is used to assess therapy-related [qol]{.smallcaps}, measures the [qol]{.smallcaps} parameters of Energy Level, Ability to Do Daily Activities, and Overall QOL. In each of the three studies, the scores for the latter three items were significantly (*p* \< 0.001) improved from baseline (Table [IV]{.smallcaps}). In the study by Glaspy and colleagues [@b5-co15_s1p010], increases in hemoglobin level were correlated with the improvements for each of the [qol]{.smallcaps} parameters independent of tumour response, and in the study by Demetri and colleagues [@b6-co15_s1p010], similar correlations were evident in patients having a complete response, a partial response, or stable disease.

Finally, the most recent Cochrane analysis included a systematic review of 9353 cancer patients enrolled into randomized controlled trials of epoetin alfa, epoetin beta, or darbepoetin alfa, updating the evidence to include trials from 1985 to 2005 [@b18-co15_s1p010]. The authors concluded that the results show an overall positive effect of epoetin on [qol]{.smallcaps} that seems unlikely to be attributable to chance.

2.3 Improvement in Cognition
----------------------------

The central nervous system has been demonstrated to contain epoetin receptors and to produce epoetin. Epoetin has been hypothesized to possibly protect neurons from injury such as ischemia, trauma, epilepsy, Parkinson disease, and disturbances of cognitive function [@b19-co15_s1p010]. The ability of [esa]{.smallcaps}s to improve cognition was demonstrated by O'Shaughnessy *et al.* [@b20-co15_s1p010] in women with breast cancer undergoing adjuvant chemotherapy. That study was followed by a randomized double-blind placebo-controlled trial to prospectively evaluate the effects of [esa]{.smallcaps}s on several factors (cognitive function, mood, asthenia, and [qol]{.smallcaps} ) [@b21-co15_s1p010] Patients were randomized to receive 40,000 IU of subcutaneous epoetin alfa or placebo every week during 4 cycles of chemotherapy over 3 months. Interim results indicated that the use of [esa]{.smallcaps} improved hemoglobin and asthenia, reduced [qol]{.smallcaps} decline, improved mood, and may have ameliorated cognitive function. Because of the small sample size, the results for cognitive function were not statistically significant; they remain hypothesis-generating only.

3. RISKS
========

3.1 Increased Risk of Thrombosis
--------------------------------

A significant side effect of drugs classified as [esa]{.smallcaps}s is an increased risk of thromboembolic events. The recently published Cochrane meta-analysis included 9353 cancer patients enrolled from 1985 to 2005 into 57 randomized placebo-controlled trials using epoetin alfa, epoetin beta, or darbepoetin alfa [@b18-co15_s1p010]. Treatment with an [esa]{.smallcaps} increased the risk of thromboembolic events \[relative risk: 1.67; 95% confidence interval ([ci]{.smallcaps}): 1.35 to 2.06\]. This risk increased proportionately as target hemoglobin rose. The causation of thromboembolic events in patients receiving erythropoietin growth factors is complex because of the increased baseline risk of thrombosis associated with chemotherapy and with cancer in general. Accepted guidelines must be adhered to, and careful follow-up of patients is mandatory.

3.2 Survival Analysis
---------------------

With regard to survival, two early studies questioned a survival benefit for [esa]{.smallcaps}s given to cancer patients. More recently, two additional trials demonstrated a negative effect on overall survival. These four negative trials that resulted in shorter survival deserve discussion.

The Breast Cancer Erythropoietin Survival Trial ([best]{.smallcaps}) [@b22-co15_s1p010] was a randomized trial in metastatic breast cancer. Patients who were not anemic received epoetin alfa or placebo, aiming to achieve a hemoglobin level of 12--14 g/dL. Decreased survival at 1 year \[hazard ratio ([hr]{.smallcaps}): 1.35\] was seen in the group treated with epoetin alfa, with most of the deaths occurring in the first 4 months, possibly secondary to thrombotic cardiac vascular events. The aim for higher-than-standard hemoglobin levels may explain this result and is now discouraged.

The [enhance]{.smallcaps} trial [@b23-co15_s1p010] was a study in patients with head-and-neck cancer randomized to either placebo or epoetin beta to achieve hemoglobin levels of 14.5--15 g/dL. Patients were not anemic, and they received radiation, but not chemotherapy. Again, a decrease in survival ([hr]{.smallcaps}: 1.39) was seen in the [esa]{.smallcaps}-treated group, who, like the [best]{.smallcaps} trial patients, were being treated to reach above-standard hemoglobin levels.

The [epo-can]{.smallcaps} 20 trial [@b24-co15_s1p010] was a randomized trial in non-small-cell lung cancer patients who were anemic. Patients studied were not on active treatment with either high-dose thoracic radiation or platinum-based chemotherapy. Because an increase in the risk of thrombosis was being recognized as feature of [esa]{.smallcaps}s, an unplanned safety analysis was performed after 70 patients had been randomized. The median survival favoured the patients on the placebo arm ([hr]{.smallcaps}: 1.84), and the study closed. Given the early high mortality and the extremely small sample size, drawing any conclusions was hard. The application of the trial was also questioned, because [esa]{.smallcaps} use in cancer patients not on active treatment is not common practice.

Finally, Amgen 20010103 was a randomized trial of darbepoetin alfa in cancer patients who were anemic and, as in [epo]{.smallcaps}-[can]{.smallcaps} 20, not on active cancer therapy. Results were reported in letter format only in *The Cancer Letter* [@b25-co15_s1p010]. The primary endpoint, reduction in transfusion, was not met, and an increase in mortality ([hr]{.smallcaps}: 1.30) was seen in the [esa]{.smallcaps} arm. The dosing regimen was not consistent with the approved darbepoetin alfa product monograph. Follow-up was only 4.3 months, and further follow-up and analysis will be ongoing. As was seen in [epo]{.smallcaps}-[can]{.smallcaps} 20, the use of [esa]{.smallcaps}s in patients not on active treatment is not common practice and is now discouraged.

In summary, of the four negative survival trials, the first two treated patients so as to reach higher-than-standard hemoglobin levels, and the second two were conducted in cancer patients not on active treatment. All four were studying [esa]{.smallcaps}s outside of the standard guidelines and indications.

Multiple randomized trials have been published showing no survival disadvantage with the use of [esa]{.smallcaps}s. Most recently, in large randomized trials of lung cancer patients receiving chemotherapy, early versus late intervention with epoetin alfa [@b26-co15_s1p010] and a placebo-controlled comparison of darbepoetin [@b13-co15_s1p010] revealed no survival decrement. A randomized double-blind placebo-controlled trial of epoetin alfa in treatment of patients with small-cell lung cancer was published in the *Journal of Clinical Oncology* in 2005 [@b27-co15_s1p010]. That study also closed prematurely, not because of safety concerns, but because of low accrual. Baseline hemoglobin values were 12.8 g/dL and 13 g/dL in the two groups at the time of initiation of treatment. The primary endpoint---overall tumour response---was not significantly different at 72% for the epoetin alfa group and 67% for placebo. Hemoglobin was stable in the epoetin alfa group and decreased in the placebo group. Even though treatment with epoetin alfa was outside the current guidelines, survival in both groups was similar.

In terms of survival, the first Cochrane analysis reported inconclusive evidence that erythropoietin may improve overall survival ([hr]{.smallcaps}: 0.81; 95% [ci]{.smallcaps}: 0.67 to 0.99). Trials through December 2001 were included. The more recent analysis that incorporated trials up to 2005 included the [best]{.smallcaps}, [enhance]{.smallcaps}, and [epo]{.smallcaps}-[can]{.smallcaps} 20 studies. This latter analysis resulted in a hazard ratio of 1.08 (95% [ci]{.smallcaps}: 0.99 to 1.18). The authors concluded that there was uncertainty regarding "whether and how epoetin or darbepoetin effects overall survival" [@b18-co15_s1p010].

3.3 Tumour Progression
----------------------

Finally, tumour progression secondary to activation of erythropoietin receptors has been questioned [@b28-co15_s1p010]. Both [best]{.smallcaps} and [enhance]{.smallcaps} showed decreased tumour control, but as discussed earlier, both used unapproved dosing regimens. A third study deserves mention. The [dahanca]{.smallcaps} trial [@b29-co15_s1p010] followed the [enhance]{.smallcaps} study and was designed to avoid the numerous protocol violations in [enhance]{.smallcaps} and subsequent difficulty in interpreting the results. As a prospective trial in head-and-neck squamous cell carcinoma in patients who were undergoing treatment with definitive radiotherapy, [dahanca]{.smallcaps} planned to randomize 600 patients to darbepoetin alfa or placebo. Its primary objective was the 5-year locoregional control rate. An interim analysis in 484 patients demonstrated a 10% increase in the locoregional failure rate among patients treated with darbepoetin alfa (*p* = 0.01). Overall survival was not significantly different, but did trend toward shorter survival in the [esa]{.smallcaps} arm (*p* = 0.08). This study had many limitations. The dosing regimen and dose adjustment rules for darbepoetin alfa were not approved. The target hemoglobin was 14--15.5 g/dL. As well, the design of the study was not adequate to assess tumour proliferation, because no uniform imaging assessment was conducted at baseline or at recurrence, nor was proliferation confirmed by biopsy. To further complicate the interpretation of study results, patients were treated with a hypoxic radiosensitizer, nimorazole, which is not routine practice. Moreover, nimorazole has not been studied for safety when given in combination s with [esa]{.smallcaps} [@b30-co15_s1p010]. The final study analysis will be reported to the [fda]{.smallcaps} in late 2008.

The relationship between the presence of erythropoietin receptors and tumour proliferation attributable to exogenous erythropoietin with the use of [esa]{.smallcaps}s has not been established. Outside of simple presence, the function of erythropoietin receptors is not well understood. *In vitro* studies vary in their conclusions. If erythropoietin has a direct effect on tumour cell growth, then cancer cells must express functional erythropoietin receptors or protein on their surface. The commercial antibody used to detect such receptors is Santa-Cruz C-20. This antibody lacks specificity and cannot distinguish cell-surface expression from intracellular expression [@b31-co15_s1p010]. The results of further studies must be awaited.

In summary, the risk of thrombosis and embolism is definitely increased with the use of [esa]{.smallcaps}s. Careful monitoring of hemoglobin levels in patients is mandatory. The negative survival studies are difficult to interpret because of target hemoglobin levels higher than those recommended, poor study design, and enrolment of patients not on active care. The trials showing tumour progression suffer from similar limitations.

4. SUMMARY
==========

Cancer-related anemia impairs patient functioning through a variety of direct and indirect mechanisms. A large body of evidence demonstrates that treatment with [esa]{.smallcaps}s of anemia in cancer patients on active chemotherapy significantly increases hemoglobin levels, reduces the requirement for transfusions, and improves [qol]{.smallcaps}. In addition, gains in cognitive function are hypothesized.

Risks are also associated with [esa]{.smallcaps}s: Safety issues include increased thromboembolic risk. As well, four studies show decreased survival and three studies suggest tumour proliferation with the use of [esa]{.smallcaps}s. All of these findings are limited, because all of the studies used unapproved dosing regimens or aimed for hemoglobin levels higher than generally recommended. Attention to the target hemoglobin of 12 g/dL must be emphasized. Adherence to guidelines concerning [esa]{.smallcaps}s in the management of cancer patients on active treatment should be mandatory.

In May 2004, the [fda]{.smallcaps}'s Oncologic Drugs Advisory Committee ([odac]{.smallcaps}) revised product labelling to include warnings against maintaining hemoglobin levels above 12 g/dL. Given the decreased survival seen in the Amgen 20010103 study discussed earlier, the [odac]{.smallcaps} met again in May 2007. "Black box" warnings were initiated in both Canada and the United States. The panel voted to have Amgen and Johnson & Johnson further strengthen the warning labels of their [esa]{.smallcaps}s and carry out additional safety studies on the drugs. A final report from the [fda]{.smallcaps} is still pending.

###### 

Proportion of patients on epoetin alfa ([epo]{.smallcaps}) transfused during chemotherapy

  ------------------------------------------------------------------------
  Chemotherapy regimen   Patients transfused (%)                      
  ---------------------- ------------------------- ---- ------------- ----
  Without cisplatin      44                        44   21            33

  With cisplatin         50                        63   23\           56
                                                        *p* \< 0.05   

  Combined               47                        53   22\           43
                                                        *p* \< 0.05   
  ------------------------------------------------------------------------

###### 

Proportion of patients on darbepoetin alfa transfused during chemotherapy

  Period                       Patients transfused                      
  ---------------------------- --------------------- ------------- ---- ----
  Week 5 to end of treatment   31                    27            77   52
                               (*N =* 148)           (*N =* 149)        

###### 

Quality of life ([qol]{.smallcaps}) outcomes in Littlewood *et al.* [@b11-co15_s1p010]

            Evaluable for   Overall [qol]{.smallcaps}   Energy level       Daily activities          Other [qol]{.smallcaps}                                                                                     
  --------- --------------- --------------------------- ------------------ ------------------ ------ ------------------------- ------ -------- ---------------------------------------------- ------------------ ------------------
  Control   115             108                         [na]{.smallcaps}                      −5.8                             −6.0                                                                              
  Epoetin   244             227                         [na]{.smallcaps}   \<0.01             7.8    \<0.001                   7.3    \<0.01                                                                     
  Control   115             90                                                                                                                 [fact]{.smallcaps}-[an]{.smallcaps}: anemia    −9.4               
  Epoetin   244             200                                                                                                                [fact]{.smallcaps}-[an]{.smallcaps}: anemia    14.4               \<0.01
  Control   115             90                                                                                                                 [fact]{.smallcaps}-[an]{.smallcaps}: fatigue   −4.2               
  Epoetin   244             200                                                                                                                [fact]{.smallcaps}-[an]{.smallcaps}: fatigue   5.7                \<0.01
  Control   115             [na]{.smallcaps}                                                                                                   [sf]{.smallcaps}-36                            [na]{.smallcaps}   
  Epoetin   244             [na]{.smallcaps}                                                                                                   [sf]{.smallcaps}-36                            [na]{.smallcaps}   [ns]{.smallcaps}

[na]{.smallcaps} = not available; [fact]{.smallcaps}-[an]{.smallcaps} = Functional Assessment of Cancer Therapy--Anemia; [sf]{.smallcaps}-36 = Medical Outcomes Study Short Form--36.

###### 

Quality of life ([qol]{.smallcaps}) outcomes [a](#tfn2-co15_s1p010){ref-type="table-fn"} in community-based studies

  [qol]{.smallcaps} parameter   Mean change in [lasa]{.smallcaps} score from baseline \[mm (%)\]               
  ----------------------------- ------------------------------------------------------------------ ----------- -----------
  Energy level                  15.0 (38)                                                          11.5 (29)   11.9 (30)
  Ability in daily activities   13.9 (32)                                                          11.2 (28)   10.8 (27)
  Overall qol                   11.0 (24)                                                          9.8 (21)    9.3 (20)

All results in this table: *p* \< 0.01 versus baseline.
